Hepatitis B Proof of Concept study
You are here
20/03/2015
Aim: Assessment of immunogenicity and safety of intradermal injection of HepatitisB vaccine antigen using VAX-ID™
Partners: University of Antwerp (Product Development, VAXINFECTIO), Voxdale bvba, Novosanis nv
- 48 healthy volunteers, aged 18-35 years
- Inclusion criterium: known HBV titers at baseline
- Comparison route of administration (ID and IM) and ID administration (Mantoux technique and VAX-ID™)
Conclusion: Intradermal adminstration of HepatitisB vaccine resulted in higher immune responses compared to intramuscular administration. Mild solicited local reactions after ID injections were most likely caused by the aluminum adjuvans. VAX-ID was thus shown to be effective for ID injections using HepatitisB vaccine and even superior to IM.